Drugs / PLZ4-coated paclitaxel-loaded micelles
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05519241 | Oct 2022 → Aug 2026 overdue | non-invasive bladder urothelial carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLZ4-coated paclitaxel-loaded micelles | “We developed a novel, solvent-free, cancer-specific nanoparticle, PLZ4-coated paclitaxel-loaded micelles (PPM), designed for targeted drug delivery and enhanced efficacy.” PMID 42415671 ↗ Jul 2026 |
| Known as | PPM | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05519241 ↗ |
| Modality | Other / unclassified | “We developed a novel, solvent-free, cancer-specific nanoparticle, PLZ4-coated paclitaxel-loaded micelles (PPM), designed for targeted drug delivery and enhanced efficacy.” PMID 42415671 ↗ Jul 2026 |